NCT07179484

To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

An Open-label, Single-arm, Multicenter Phase Ib Clinical Trial Evaluating the Efficacy, Safety, and Cellular Metabolism Kinetics of CT041 Autologous CAR-T Cell Injection as a Sequential Therapy Following First-line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Beijing GoBroad Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of CT041 in sequential treatment after first-line treatment of advanced gastric/esophagogastric junction adenocarcinoma

Conditions

• Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	CT041 autologous CAR T-cell injection	The planned dose of CT041 is 2.5×108 cells. The participants are recommended to receive only a single infusion or multiple infusions (up to 3 infusions) according to the safety and efficacy data of the participants per the investigator. The dose and method of re-infusion are the same as the first infusion. Lymphodepletion pretreatment should be given before re-infusion, and the requirements before lymphodepletion pretreatment and cell infusion should also be met before re-lymphodepletion pretreatment or re-infusion.

Timeline

• Start date: 2025-10-22
• Primary completion: 2027-09-01
• Completion: 2028-09-01
• First posted: 2025-09-17
• Last updated: 2025-10-01

Locations

1 site across 1 country: China